Phosphatidylinositol-3-Kinase Signaling Is Required for Erythropoietin-Mediated Acute Protection Against Myocardial Ischemia/Reperfusion Injury
- 4 May 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 109 (17) , 2050-2053
- https://doi.org/10.1161/01.cir.0000127954.98131.23
Abstract
Background— Parenteral administration of recombinant human erythropoietin (rhEPO) to rats induces protection against myocardial ischemia/reperfusion injury 24 hours later. However, the mechanisms by which rhEPO mediates protection have not been determined. Methods and Results— rhEPO was perfused into isolated rat hearts over 15 minutes immediately before 30 minutes of no-flow ischemia and 45 minutes of reperfusion. Compared with saline-perfused control hearts, recovery of left ventricular developed pressure was increased in rhEPO-perfused hearts. rhEPO also increased AKT activity and decreased apoptosis. All of these effects were blocked when the phosphatidylinositol-3-kinase inhibitor wortmannin was infused with rhEPO. Conclusions— rhEPO provides immediate protection against ischemia/reperfusion injury in the isolated perfused rat heart that is mediated by the phosphatidylinositol-3-kinase pathway.Keywords
This publication has 15 references indexed in Scilit:
- A novel protective effect of erythropoietin in the infarcted heartJournal of Clinical Investigation, 2003
- Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathwayBiochemical and Biophysical Research Communications, 2003
- Hearts From Rodents Exposed to Intermittent Hypoxia or Erythropoietin Are Protected Against Ischemia-Reperfusion InjuryCirculation, 2003
- Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodelingProceedings of the National Academy of Sciences, 2003
- Myocyte apoptosis: programming ventricular remodeling**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.Journal of the American College of Cardiology, 2003
- Erythropoietin Is a Novel Vascular Protectant Through Activation of Akt1 and Mitochondrial Modulation of Cysteine ProteasesCirculation, 2002
- Protective responses in the ischemic myocardiumJournal of Clinical Investigation, 2000
- Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathwayKidney International, 2000
- Cellular survival: a play in three AktsGenes & Development, 1999
- Cytokine receptor signallingNature, 1995